ER doctors seeing more Hepatitis C cases among injection drug users
October 27, 2016
Living a full life with Crohn’s
October 27, 2016
Show all

RA Drug Candidate Baricitinib Shows Promise as Potential Therapy

The medication baricitinib could benefit joint health in those with rheumatoid arthritis.

Treatment with baricitinib improves joint damage in patients with rheumatoid arthritis (RA) who have an inadequate response or intolerance to conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), according to the results of a Phase 3 clinical trial developed by the pharmaceutical companies Incyte and Eli Lilly.

The study was conducted by a team of international researchers and published under the title “Baricitinib In Patients With Inadequate Response Or Intolerance To Conventional Synthetic Dmards: Results From The RA-BUILD Study” in the journal Annals of the Rheumatic Diseases.

Baricitinib is an oral drug under evaluation for the treatment of inflammatory and autoimmune diseases. It preferentially inhibits the proteins Janus kinase (JAK) 1 and JAK2, both of which are widely expressed and responsible for inflammatory reactions associated with the pathology of RA.

The Phase 3 study (Ra-BUILD; NCT01721057) included 684 patients (18 years and older) from 22 countries with moderate to severely active RA and an inadequate response or intolerance to at least one conventional synthetic DMARD. The participants were divided into subgroups according to the region and presence of joint erosions, and were randomly assigned to either a placebo or baricitinib (2 or 4 mg) once daily.

The endpoints of the study were achieved if the patients’ response included an American College of Rheumatology 20% response (ACR20), Disease Activity Score (DAS28) and Simplified Disease Activity Index (SDAI) score below or equal to 3.3, all of which are indicators of disease improvement.

Read Full Article: RA Drug Candidate Baricitinib Shows Promise as Potential Therapy

Read Full Article: RA Drug Candidate Baricitinib Shows Promise as Potential Therapy

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.